Butterbur (Petasites hybridus) is a perennial shrub with a long history of traditional use in Europe, and modern research has brought renewed attention to its potential benefits. Studies indicate that standardized butterbur extract may help support comfort during allergy season, with some clinical trials suggesting it performs comparably to certain conventional antihistamines in easing seasonal nasal discomfort. Research also suggests promising results for migraine frequency reduction, and preliminary studies have explored its role in supporting respiratory health for those with asthma-related concerns. It is important to note that only PA-free (pyrrolizidine alkaloid-free) extracts are considered appropriate for use, as raw or unprocessed butterbur contains compounds that may be harmful to the liver. As with any supplement, consulting a healthcare provider is a wise starting point.
Compare this supplementResearch suggests that butterbur, particularly extracts derived from Petasites hybridus and related species, shows so...
View studies →Research suggests that Butterbur may hold some promise as a complementary approach to allergic rhinitis relief, thoug...
View studies →Research suggests that butterbur has attracted attention as a potential option for migraine prevention, and it appear...
View studies →These are commonly referenced dosage ranges for this supplement. They are not medical recommendations. Always consult a healthcare provider before supplementing.
| Form | Dose range | Frequency | Studied for | Source |
|---|---|---|---|---|
| Extract | 8–16 mg | Twice daily | Allergy relief and seasonal allergic rhinitis | Based on standardized Ze339 extract RCTs; Schapowal et al. 2002 BMJ |
| Extract | 50–75 mg | Twice daily | Asthma support | Used in pilot studies on bronchial asthma; Danesch 2004 Altern Med Rev |
| Extract | 50–75 mg | Twice daily | Migraine prevention | Common in RCTs; 75mg twice daily shown superior in Lipton et al. 2004 Neurology trial |
| Extract | 50 mg | Twice daily | Migraine prevention (lower dose) | Used as comparison arm in clinical trials including Lipton et al. 2004 |